{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:23:26Z","timestamp":1762842206254,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":53,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Shanghai Municipality Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009018","name":"Shanghai Municipal Human Resources and Social Security Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014175","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100345","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T23:54:31Z","timestamp":1614124471000},"page":"100345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report"],"prefix":"10.1016","volume":"27","author":[{"given":"Xiaomin","family":"Niu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingzi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"Cancer Facts Figures","article-title":"American cancer society","year":"2017","key":"10.1016\/j.ctarc.2021.100345_bib0001"},{"key":"10.1016\/j.ctarc.2021.100345_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2016.02.007","article-title":"Diffuse malignant mesothelioma and synchronous lung cancer: a clinicopathological study of 18 cases","volume":"95","author":"Butnor","year":"2016","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100345_bib0003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2559.2003.01685.x","article-title":"Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals","volume":"43","author":"Attanoos","year":"2003","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100345_bib0004","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctarc.2021.100345_bib0005","first-page":"45","article-title":"Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: a case report","volume":"26","author":"Yamazoe","year":"2018","journal-title":"Respir Med Case Rep"},{"issue":"12","key":"10.1016\/j.ctarc.2021.100345_bib0006","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/cncy.21342","article-title":"The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey","volume":"121","author":"Paintal","year":"2013","journal-title":"Cancer Cytopathol"},{"issue":"10026","key":"10.1016\/j.ctarc.2021.100345_bib0007","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100345_bib0008","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctarc.2021.100345_bib0009","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100345_bib0010","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100345_bib0011","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:20:47Z","timestamp":1762842047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221000447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":11,"alternative-id":["S2468294221000447"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100345","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100345"}}